A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

NCT05587309 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1250

Enrollment

INDUSTRY

Sponsor class

Conditions

Erosive Esophagitis

Interventions

DRUG: BLI5100
DRUG: PPI Control

Sponsor

Braintree Laboratories